Opendata, web and dolomites

MEDMICO

Moving to Efficient Diabetes care: Multimode Integrated CO-morbidity diagnostics platform

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEDMICO project word cloud

Explore the words cloud of the MEDMICO project. It provides you a very rough idea of what is the project "MEDMICO" about.

accuracy    patient    lipids    comorbidity    patients    innovation    clinical    mode    shelf    efficient    tests    shift    optimal    launch    outcomes    2013    turbidimetry    life    storage    projections    epidemic    forefront    lab    biomaterials    extensive    college    disruptive    validated    pharmacies    platform    revenues    care    incumbent    comorbidities    kidney    disease    submission    incorporates    near    diabetes    vitro    breakthrough    room    drive    diagnostics    immunoassays    complications    cell    months    positioning    pilot    central    segments    diagnostic    primary    prototype    adult    rising    12    counting    contractor    validation    clinics    2035    hba1c    multiple    quad    point    dublin    spearhead    ready    renal    poct    panels    majority       1st    laboratories    monitor    population    combat    morbid    provides    temperature    diagnose    date       expertise    chemistry    usability    sub    precision    workflow    away    pipette    sensitivity    screen    efficiencies    single    regulatory    diabetic    healthcare    radisens    comorbid    integrating    trials    delivering    cardiovascular    trl8    outpatient    evidenced    co    gt    abnormalities    heart    medmico    ischemic    trinity    creatinine   

Project "MEDMICO" data sheet

The following table provides information about the project.

Coordinator
RADISENS DIAGNOSTICS LIMITED 

Organization address
address: UNITS 1-3 WESTPOINT BUILDINGS LINK ROAD BALLINCOLL
city: CORK
postcode: IP31 HF29
website: www.radisens.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.radisens.com/
 Total cost 4˙487˙525 €
 EC max contribution 4˙487˙525 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RADISENS DIAGNOSTICS LIMITED IE (CORK) coordinator 4˙487˙525.00

Map

 Project objective

Diabetes affects 8.5% (2013) of the adult European population rising to 10.3% (2035) and is associated with co-morbid conditions such as cardiovascular and renal abnormalities. These lead to diabetic complications, ischemic heart disease, heart failure and kidney failure. Management of this growing epidemic requires a shift in care management and delivery, away from lab testing. The majority of current diagnostic testing for diabetes and comorbidities involves central laboratories as incumbent in-vitro diagnostic point-of-care testing (PoCT) provides sub-optimal accuracy and single tests (rather than needed panels) for diabetes and its comorbidities. MEDMICO will spearhead a diagnostic breakthrough by delivering the 1st quad-mode PoCT platform integrating immunoassays, turbidimetry, clinical chemistry and cell counting. HbA1c, Lipids and Creatinine tests will be integrated on to a single diabetes comorbid platform with state-of-the-art sensitivity/precision, room temperature storage, >12 months’ shelf-life and integrated pipette to screen, diagnose and monitor patients, within primary care, outpatient clinics and pharmacies. This will improve patient outcomes and healthcare efficiencies, positioning Europe at the forefront of healthcare innovation and deliver an efficient platform to combat this epidemic. MEDMICO incorporates extensive technical, clinical and exploitation expertise - Radisens’ disruptive PoCT prototype and Trinity College Dublin (sub-contractor) biomaterials expertise and diabetes patient access. MEDMICO’s potential is evidenced by Radisens’ revenues to date and large near-term projections from diagnostics partners before its launch. Existing research of end-user needs and workflow assessment will drive platform development and pilot production, with clinical validation and usability trials in multiple PoCT segments to TRL8. This will deliver a validated quad-mode diabetes comorbidity platform, ready for regulatory submission.

 Deliverables

List of deliverables.
Target stakeholder web site & project presentation Websites, patent fillings, videos etc. 2019-07-24 15:31:59

Take a look to the deliverables list in detail:  detailed list of MEDMICO deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEDMICO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEDMICO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More